DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Des Guetz G. et al.
Anti PD-1 (nivolumab, pembrolizumab) or anti PD-L1 (atezolizumab) versus docetaxel for previously treated patients with advanced NSCLC: A meta-analysis.
J Clin Oncol; 2016
34. (suppl; abstr e20555)
We do not assume any responsibility for the contents of the web pages of other providers.